Enhertu ^*

Enhertu (active ingredient fam-trastuzumab deruxtecan-nxki) is an advanced antibody-drug conjugate (ADC) designed to target cancers that express the HER2 protein. The monoclonal antibody component binds specifically to HER2 on the surface of cancer cells, enabling the linked chemotherapy moiety to be internalized and released inside the tumor cell, where it interferes with DNA replication and triggers cancer cell death. This targeted approach aims to deliver potent therapy directly to tumor cells while limiting exposure to healthy tissues. Enhertu is prescribed for adults with unresectable or metastatic HER2-positive breast cancer who have previously received anti-HER2 therapy, and for patients with HER2-low breast cancer, HER2-mutant non-small cell lung cancer, and locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma, according to approved indications. Patient eligibility is carefully determined based on tumor HER2 status and prior treatments. Because Enhertu delivers a potent cytotoxic agent, treatment is administered intravenously by a qualified oncologist, and patients are monitored for side effects, which can include nausea, fatigue, and others. Due to risks such as interstitial lung disease and other serious toxicities, close clinical follow-up is essential throughout the course of therapy.